Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
Copyright SPH Media. All rights reserved.
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
